Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)

DRUG2 trials

Sponsors

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Conditions

Acute Coronary Syndrome

Phase 1

Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome

CompletedNCT06618495

Xiyuan Hospital of China Academy of Chinese Medical SciencesAcute Coronary Syndrome

Start: 2024-12-23End: 2025-11-25Updated: 2025-12-02

Phase 3

Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol

Not yet recruitingNCT06845254

Xiyuan Hospital of China Academy of Chinese Medical SciencesAcute Coronary Syndrome

Start: 2025-03-01End: 2026-12-01Target: 400Updated: 2025-02-25